1. A system for passing TDM traffic through a packet switch, comprising
a packet switch having a plurality of data ports and configured to route FSDU (fixed sized data unit) packets between the plurality of data ports;
a TDM encapsulation circuit coupled to a data flow of TDM data and having a circuit demultiplexer for processing an incoming data flow of TDM data to buffer data associated with different TDM circuits into different buffer locations, and for accessing a connection table having information representative of the plurality of data ports being supported by the packet switch including two or more data ports associated with a respective route through which an FSDU associated with a respective circuit is routed by the packet switch,
a timer for monitoring a frame boundary, and
a FSDU generator for generating an FSDU and filling the generated FSDU with data associated with a respective one of the TDM circuits and for generating header information representative of information for allowing the packet switch to route the generated FSDU to a respective one of said plurality of data ports, said respective port being associated with the respective one of the TDM circuits.
2. A system according to claim 1, further comprising
a merge circuit for merging the generated FSDU with packet flow data being sent to the packet switch.
3. A system according to claim 1, further comprising
a decapsulation circuit for processing a generated FSDU passed through the packet switch to provide data to one or more TDM circuits sending data from a port of the packet switch.
4. A system according to claim 1, further including
a priority switch for associating a routing priority level with a generated FSDU.
5. A system according to claim 4, further comprising
a bandwidth allocation process for allocating bandwidth for generated FSDU traffic to provide a predetermined latency period for routing traffic through the packet switch.
6. A system according to claim 1, further comprising
a jitter buffer for reducing variable delays arising from passing through the packet switch.
7. A system according to claim 6, wherein
the jitter buffer has a size selected as a function of a minimum and maximum latency for data passing through the packet switch.
8. A system according to claim 6, wherein
the jitter buffer has a size selected to maintain jitter below 125 microseconds.
9. A system according to claim 1, wherein
the packet switch includes ports capable of supporting a combination of traffic types.
10. A system according to claim 1, wherein
traffic types include packet type traffic and TDM type traffic.
11. A system according to claim 1, further comprising a dropped-circuit detector for detecting a dropped TDM circuit.
12. A system according to claim 11, wherein the FSDU generator responds to the dropped-circuit detector to adjust the contents of the FSDU.
13. A process for passing TDM traffic through a packet switch, comprising
providing a packet switch having a plurality of data ports and configured to route FSDU packets between the plurality of data ports;
identifying a TDM data flow,
encapsulating the TDM data flow by sorting the TDM data flow into different respective buffer locations,
accessing a connection table having information representative of the plurality of data ports being supported by the packet switch including two or more data ports associated with a respective route through which an FSDU packet associated with a respective circuit is routed by the packet switch,
generating an FSDU that can pass through the packet switch and filling the generated FSDU with data associated with a respective one of the TDM circuits,
generating header information representative of information for routing the generated FSDU to one of said plurality of data ports associated with the respective one of the TDM circuits, and
combining the generated FSDU with a flow of packet data being sent to the packet switch.
14. A process according to claim 13, further comprising processing a generated FSDU having been passed through the packet switch to reconstruct a TDM data flow circuit at an output port of the packet switch.
15. A process according to claim 14, further comprising monitoring the number of TDM circuits within the TDM data flow to identify a change in the number of TDM circuits.
16. A process according to claim 15, further comprising altering the contents of the generated FSDU as a function of a detected change in the number of circuits in the TDM data flow.
17. A process according to claim 13, further comprising setting a timer to establish a time period for filling the generated FSDU.
18. A process according to claim 17, wherein the time period is set to the TDM frame boundary period.
19. A process according to claim 13, further comprising buffering a generated TDM circuit at an output port to reduce latency induced time variations.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of Formula I:
or its pharmaceutically acceptable salt or prodrug thereof, wherein:
R1 is a piperazinyl, which can be optionally substituted by 1, 2, 3 or 4 R1a;
R1a is H, halogen, cyano-group, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 haloalkyl, C1-6 cyanoalkyl, ORa, SRa, NRbRc, NRbC(O)Rd, NRbS(O)2Rd, C(O)NRbRc, C(O)Rd, C(O)ORa, S(O)2Rd, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein the said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl can be optionally substituted with 1, 2 or 3 groups independently selected from cyano-group, halogen, ORa, SRa, NRbRc, NRb(CO)Rd, NRbS(O)2Rd, C(O)NRbRc, S(O)2NRbRc, C(O)Rd, C(O)ORa, S(O)2Rd, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
Alternatively, two R1a groups taken together with the atoms attached to them can form a cycloalkyl and heterocycloalkyl of 3, 4, 5, 6 or 7-membered ring, and can be optionally substituted by 1, 2 or 3 groups independently selected from cyano-group, halogen, ORa, SRa, NRbRc, NRb(CO)Rd, NRbS(O)2Rd, C(O)NRbRc, S(O)2 NRbRc, C(O)Rd, C(O)ORa, S(O)2Rd, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
R2 is H, halogen, cyano-group, ORa, SRa, NRbRc, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 haloalkyl, C1-6 cyanoalkyl, C2-6 alkenyl or C2-6 alkynyl;
Alternatively, two R2 groups taken together with the atoms attached to them can form a cycloalkyl and heterocycloalkyl of 3, 4, 5, 6 or 7-membered ring, and can be optionally substituted by 1, 2 or 3 groups independently selected from cyano-group, halogen, ORa, SRa, NRbRc, NRb(CO)Rd, NRbS(O)2Rd, C(O)NRbRc, S(O)2NRbRc, C(O)Rd, C(O)ORa, S(O)2Rd, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, and C2-6 alkynyl;
R3 is H, halogen, cyano-group, ORa, SRa, NRbRc, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 haloalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, cycloalkyl, or heterocycloalkyl;
Alternatively, two R3 groups taken together with the atoms attached to them can form a cycloalkyl and heterocycloalkyl of 5, 6 or 7-membered ring, and can be optionally substituted by 1, 2 or 3 groups independently selected from halogen, cyano-group, ORa, SRa, NRbRc, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, and C2-6 alkynyl;
W\u2014X is amide bond;
Y is heteroaryl, which can be optionally substituted by 1, 2 or 3 R4;
Z is heteroaryl, which can be optionally substituted by 1, 2 or 3 R5;
R4 and R5 are independently selected from halogen, cyano-group, ORa, SRa, NRbRc, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 haloalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, NRb(CO)Rd, C(O)NRbRc, NRbS(O)2Rd, S(O)2NRbRc, C(O)Rd, C(O)ORa, S(O)2Rd, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
Alternatively, two R4 or two R4 groups taken together with the atoms attached to them respectively, can form a cycloalkyl and heterocycloalkyl of 5, 6 or 7-membered ring, and can be optionally substituted by 1, 2 or 3 groups independently selected from halogen, cyano-group, ORa, SRa, NRbRc, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, and C2-6 alkynyl;
Ra, Rb, Rc and Rd are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
Alternatively, the Rb and Rc groups taken together with the nitrogen atom attached to them can form a heterocycloalkyl of 4, 5, 6 or 7-membered ring, and can be optionally substituted by 1, 2 or 3 groups independently selected from halogen, cyano-group, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
n is an integer from zero to four; and
m is an integer from zero to two.
2. A compound of Formula II:
or its pharmaceutically acceptable salt or prodrug,
wherein:
R1 is a piperazinyl, which can be optionally substituted by 1, 2, 3 or 4 R1a;
R1a is H, halogen, cyano-group, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 haloalkyl, C1-6 cyanoalkyl, ORa, SRa, NRbRc, NRbC(O)Rd, NRbS(O)2Rd, C(O)NRbRc, C(O)Rd, C(O)ORa, S(O)2Rd, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein the said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl can be optionally substituted with 1, 2 or 3 groups independently selected from cyano-group, halogen, ORa, SRa, NRbRc, NRb(CO)Rd, NRbS(O)2Rd, C(O)NRbRc, S(O)2NRbRc, C(O)Rd, C(O)ORa, S(O)2Rd, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6cyanoalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
Alternatively, two R1a groups taken together with the atoms attached to them can form a cycloalkyl and heterocycloalkyl of 3, 4, 5, 6 or 7-membered ring, and can be optionally substituted by 1, 2 or 3 groups independently selected from cyano-group, halogen, ORa, SRa, NRbRc, NRb(CO)Rd, NRbS(O)2Rd, C(O)NRbRc, S(O)2 NRbRc, C(O)Rd, C(O)ORa, S(O)2Rd, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
Y is heteroaryl, which can be optionally substituted by 1, 2 or 3 R4;
Z is heteroaryl, which can be optionally substituted by 1, 2 or 3 R5;
R4 and R5 are independently selected from halogen, cyano-group, ORa, SRa, NRbRc, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 haloalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, NRb(CO)Rd, C(O)NRbRc, NRbS(O)2Rd, S(O)2NRbRc, C(O)Rd, C(O)ORa, S(O)2Rd, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
Alternatively, two R4 or two R4 groups taken together with the atoms attached to them respectively, can form a cycloalkyl and heterocycloalkyl of 5, 6 or 7-membered ring, and can be optionally substituted by 1, 2 or 3 groups independently selected from halogen, cyano-group, ORa, SRa, NRbRc, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, and C2-6 alkynyl;
Ra, Rb, Rc and Rd are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
Alternatively, the Rb and Rc groups taken together with the nitrogen atom attached to them can form a heterocycloalkyl of 4, 5, 6 or 7-membered ring, and can be optionally substituted by 1, 2 or 3 groups independently selected from halogen, cyano-group, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl.
3. The compound or its pharmaceutically acceptable salt or prodrug thereof according to claim 1, wherein:
R1 is a piperidinyl, which can be optionally substituted by 1, 2, 3 or 4 R1a;
R1a is H, halogen, cyano-group, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 haloalkyl, C1-6 cyanoalkyl, ORa, SRa, NRbRc, NRbC(O)Rd, NRbS(O)2Rd, C(O)NRbRc, C(O)Rd, C(O)ORa, S(O)2Rd, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein the said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl can be optionally substituted by 1, 2 or 3 groups independently selected from cyano-group, halogen, ORa, SRa, NRbRc, NRb(CO)Rd, NRbS(O)2Rd, C(O)NRbRc, S(O)2 NRbC(O)Rd, C(O)ORa, S(O)2Rd, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
Alternatively, two R1a groups taken together with the atoms attached to them can form a cycloalkyl and heterocycloalkyl of 3, 4, 5, 6 or 7-membered ring, and can be optionally substituted by 1, 2 or 3 groups independently selected from cyano-group, halogen, ORa, SRa, NRbRc, NRb(CO)Rd, NRbS(O)2Rd, C(O)NRbRc, S(O)2 NRbRc, C(O)Rd, C(O)ORa, S(O)2Rd, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
Y is selected from pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, thiazolyl, isothiazolyl, imidazolyl, oxazolyl, isoxazolyl, triazolyl or pyrazolyl, and can be substituted by 1, 2, or 3 R4;
Z is selected from pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, thiazolyl, isothiazolyl, imidazolyl, oxazolyl, isoxazolyl, triazolyl, pyrazolyl, azotic oxazolyl, pyrindol, pyrrolo-pyrimidyl, pyrazolo-pyridyl, pyrazolo-pyrimidyl, quinolyl, isoquinolyl, quinazolyl, piperazinyl or morpholinyl, and can be substituted by 1, 2, or 3 R5;
R4 and R5 are independently selected from halogen, cyano-group, ORa, SRa, NRbRc, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 haloalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, NRb(CO)Rd, C(O)NRbRc, NRbS(O)2Rd, S(O)2NRbRc, C(O)Rd, C(O)ORa, S(O)2Rd, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
Alternatively, two R4 or two R5 groups taken together with the atoms attached to them respectively, can form a cycloalkyl and heterocycloalkyl of 5, 6 or 7-membered ring, and can be optionally substituted by 1, 2 or 3 groups independently selected from halogen, cyano-group, ORa, SRa, NRbRc, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, and C2-6 alkynyl;
Ra, Rb, Rc and Rd are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl; and
Alternatively, Rb and Rc taken together with the nitrogen atom attached to them respectively, can form a heterocycloalkyl of 4, 5, 6 or 7-membered ring, and can be optionally substituted by 1, 2 or 3 groups independently selected from halogen, cyano-group, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl.
4. The compound or its pharmaceutically acceptable salt or prodrug thereof according to claim 1, having Formula IIa:
wherein:
R6 and R7 are independently selected from H, cyano-group, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 haloalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, and C2-6 alkynyl;
Alternatively, R6 and R7 taken together with the atoms attached to them respectively, can form a 5, 6 or 7-membered carbocyclic or heterocyclic ring, and can be optionally substituted by 1, 2 or 3 groups independently selected from halogen, cyano-group, ORa, SRa, NRbRc, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 haloalkyl, C1-6 cyanoalkyl, C2-6 alkenyl and C2-6 alkynyl;
R8 is H, C1-6 alkyl, C2-6 hydroxyalkyl, C2-6 haloalkyl, C1-6 cyanoalkyl, C(O)NRbRc, C(O)Rd, C(O)ORa, S(O)2Rd, C3-6 alkenyl, C3-6 alkynyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, wherein the said C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl can be optionally substituted by 1, 2 or 3 groups independently selected from halogen, cyano-group, ORa, SRa and NRbRc;
Y is selected from pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, thiazolyl, isothiazolyl, imidazolyl, oxazolyl, isoxazolyl, triazolyl or pyrazolyl, and can be substituted by 1, 2, or 3 R4;
Z is selected from pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, thiazolyl, isothiazolyl, imidazolyl, oxazolyl, isoxazolyl, triazolyl, pyrazolyl, azotic oxazolyl, pyrindol, pyrrolo-pyrimidyl, pyrazolo-pyridyl, pyrazolo-pyrimidyl, quinolyl, isoquinolyl, quinazolyl, piperazinyl or morpholinyl, and can be substituted by 1, 2, or 3 R5;
R4 and R5 are independently selected from halogen, cyano-group, ORa, SRa, NRbRc, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 haloalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, NRb(CO)Rd, C(O)NRbRc, NRbS(O)2Rd, S(O)2NRbRc, C(O)Rd, C(O)ORa, S(O)2Rd, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
Alternatively, two R4 or two R5 groups taken together with the atoms attached to them respectively, can form a cycloalkyl and heterocycloalkyl of 5, 6 or 7-membered ring, and can be optionally substituted by 1, 2 or 3 groups independently selected from halogen, cyano-group, ORa, SRa, NRbRc, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl and C2-6 alkynyl;
Ra, Rb, Rc and Rd are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
Alternatively, Rb and Rc taken together with the nitrogen atom attached to them respectively, can form a heterocycloalkyl of 4, 5, 6 or 7-membered ring, and can be optionally substituted by 1, 2 or 3 groups independently selected from halogen, cyano-group, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl; and
p is an integer from one to two.
5. The compound or its pharmaceutically acceptable salt or prodrug thereof according to claim 1, having formula IIb:
wherein:
R9 and R10 are independently selected from H, C1-6 alkyl, C2-6 hydroxyalkyl, C2-6 haloalkyl, C1-6 cyanoalkyl, C(O)NRbRc, C(O)Rd, C(O)ORa, S(O)2Rd, C3-6 alkenyl, C3-6 alkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein the said C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl can be optionally substituted by 1, 2 or 3 groups independently selected from halogen, cyano-group, ORa, SRa or NRbRc;
Alternatively, R9 and R10 taken together with the atoms attached to them respectively, can form a cycloalkyl or heterocycloalkyl of 5, 6 or 7-membered ring, and can be optionally substituted by 1, 2 or 3 groups independently selected from halogen, cyano-group, ORa, SRa, NRbRc, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl;
R11 is H, halogen, cyano-group, ORa, SRa, NRbRc, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 haloalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl;
Y is selected from pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, thiazolyl, isothiazolyl, imidazolyl, oxazolyl, isoxazolyl, triazolyl or pyrazolyl, and can be substituted by 1, 2, or 3 R4;
Z is selected from pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, thiazolyl, isothiazolyl, imidazolyl, oxazolyl, isoxazolyl, triazolyl, pyrazolyl, azotic oxazolyl, pyrindol, pyrrolo-pyrimidyl, pyrazolo-pyridyl, pyrazolo-pyrimidyl, quinolyl, isoquinolyl, quinazolyl, piperazinyl or morpholinyl, and can be substituted by 1, 2, or 3 R5;
R4 and R5 are independently selected from halogen, cyano-group, ORa, SRa, NRbRc, C1-6 alkyl, C1-6 hydroxyalkyl, C1-6 haloalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, NRb(CO)Rd, C(O)NRbRc, NRbS(O)2Rd, S(O)2NRbRc, C(O)Rd, C(O)ORa, S(O)2Rd, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl;
Alternatively, two R4 or two R5 groups taken together with the atoms attached to them respectively, can form a cycloalkyl or heterocycloalkyl of 5, 6 or 7-membered ring, and can be optionally substituted by 1, 2 or 3 groups independently selected from halogen, cyano-group, ORa, SRa, NRbRc, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, and C2-6 alkynyl;
Ra, Rb, Rc and Rd are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl;
Alternatively, Rb and Rc taken together with the nitrogen atom attached to them respectively, can form a heterocycloalkyl of 4, 5, 6 or 7-membered ring, and can be optionally substituted by 1, 2 or 3 groups independently selected from halogen, cyano-group, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 cyanoalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl; and
q is an integer from zero to three.
6. The compound or its pharmaceutically acceptable salt or prodrug thereof according to claim 1, wherein the said compound is selected from:
1-(4-Methylpiperazin-1-yl)-N-(4-methyl-3-(4-pyridin-3-ylpyrimidin-2-yl)aminophenyl)-2,3-dihydro-1H-inden-5-carboxamide;
tert-Butyl 4-{5-({(4-methyl-3-(4-pyridin-3-ylpyrimidin-2-yl)aminophenyl}amino)carbonyl)-2,3-dihydro-1H-inden-1-yl}piperazin-1-carboxylate;
N-(4-Methyl-3-(4-pyridin-3-ylpyrimidin-2-yl)aminophenyl)-1-piperazin-1-yl-2,3-dihydro-1H-indene-5-carboxamide;
1-(4-Ethylpiperazin-1-yl)-N-(4-methyl-3-(4-pyridin-3-ylpyrimidin-2-yl)aminophenyl)-2,3-dihydro-1H-indene-5-carboxamide;
1-(4-Isopropylpiperazin-1-yl)-N-(4-methyl-3-(4-pyridin-3-ylpyrimidin-2-yl)aminophenyl)-2,3-dihydro-1H-indene-5-carboxamide;
1-4-(2-Hydroxyethyl)piperazin-1-yl-N-(4-methyl-3-(4-pyridin-3-ylpyrimidin-2-yl)aminophenyl)-2,3-dihydro-1H-indene-5-carboxamide;
1-4-Acetylpiperazin-1-yl)-N-(4-methyl-3-(4-pyridin-3-ylpyrimidin-2-yl)aminophenyl)-2,3-dihydro-1H-indene-5-carboxamide;
N-3-(4,5\u2032-Bipyrimidin-2-ylamino)-4-methylphenyl-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-indene-5-carboxamide;
1-(3S)-3-(Dimethylamino)pyrrolidin-1-yl-N-{4-methyl-3-(4-pyridin-3-ylpyrimidin-2-yl)aminophenyl}-2,3-dihydro-1H-indene-5-carboxamide;
1-(3R)-3-(Dimethylamino)pyrrolidin-1-yl-N-{4-methyl-3-(4-pyridin-3-ylpyrimidin-2-yl)aminophenyl}-2,3-dihydro-1H-indene-5-carboxamide;
(1S)-1-(4-Methylpiperazin-1-yl)-N-(4-methyl-3-(4-pyridin-3-ylpyrimidin-2-yl)aminophenyl)-2,3-dihydro-1H-indene-5-carboxamide;
(1R)-1-(4-Methylpiperazin-1-yl)-N-(4-methyl-3-(4-pyridin-3-ylpyrimidin-2-yl)aminophenyl)-2,3-dihydro-1H-indene-5-carboxamide;
(1S)\u2014N-3-(4,5\u2032-Bipyrimidin-2-ylamino)-4-methylphenyl-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-indene-5-carboxamide;
(1R)\u2014N-3-(4,5\u2032-Bipyrimidin-2-ylamino)-4-methylphenyl-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-indene-5-carboxamide;
(1S)-1-(4-Methylpiperazin-1-yl)-N-(4-methyl-3-(4-pyridin-4-ylpyrimidin-2-yl)aminophenyl)-2,3-dihydro-1H-indene-5-carboxamide; and
(1S)-1-(4-Methylpiperazin-1-yl)-N-(4-methyl-3-(4-pyridin-3-ylpyrimidin-2-yl)aminophenyl)-2,3-dihydro-1H-indene-5-carboxamide sulfate.
7. A pharmaceutical composition, wherein said pharmaceutical composition comprises the compound or pharmaceutically acceptable salt or prodrug of claim 1, and at least one pharmaceutically acceptable carrier.